نتایج جستجو برای: ras mutations

تعداد نتایج: 198454  

2000
Marc Bissonnette Sharad Khare Friederike C. von Lintig Ramesh K. Wali Lan Nguyen Yingchun Zhang John Hart Susan Skarosi Nissi Varki Gerry R. Boss Thomas A. Brasitus

Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for b-catenin. Prior in vitro studies have also demonstrated that wild type p21 can be activated by epigenetic events. We identified 15 K-ras mutations in 14 of 84 AOM-induced colonic tumors by three independent methods. By single strand conformational polym...

2017
Kaoru Kaseda Keisuke Asakura Akio Kazama Yukihiko Ozawa

BACKGROUND This study aimed to evaluate mutations of the epidermal growth factor receptor (EGFR) and K-ras genes and their clinicopathological and prognostic features in patients with resected pathological stage I adenocarcinoma. METHODS We examined 224 patients with surgically resected lung adenocarcinoma and analyzed the prognostic and predictive value of these mutations in 162 patients wit...

2012
Manolo D'Arcangelo Federico Cappuzzo

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease due to the presence of different clinically relevant molecular subtypes. Until today, several biological events have been identified in lung adenocarcinoma, including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations, offering new hopes to patients with metastatic disease. Unfortuna...

Journal: :Cancer research 1994
C Caldas S A Hahn R H Hruban M S Redston C J Yeo S E Kern

Pancreatic adenocarcinoma is the fifth leading cause of cancer death in the United States. Mutations in the K-ras oncogene occur in 85% of pancreatic adenocarcinomas and have also been identified in 75% of pancreatic ducts with mucinous cell hyperplasia seen in association with chronic pancreatitis. We identified K-ras mutations in 65% of duct lesions associated not only with chronic pancreatit...

2010
Deepika Ponnala Sujatha Madireddi Smita C Pawar

The frequency and clinicopathologic significance of the K-ras gene point mutation in stomach cancer remain to be defined. We investigated the frequency of K-ras codon 12 point mutations in stomach cancer using a polymerase chain reaction (PCR)-based method in 94 samples and 100 age and sex matched controls. The overall frequency of K-ras codon 12 point mutations in stomach cancer was 3.19% (3/9...

Journal: :Journal of the National Cancer Institute 2003
Milo Frattini Debora Balestra Silvana Pilotti Lucio Bertario Marco A Pierotti

Despite the potential effectiveness of colonoscopy and fecal occult blood tests in reducing colorectal cancer mortality, more specific, noninvasive tests are desirable. In this regard, it is possible to detect specific mutations of several genes in stool samples from colorectal cancer patients. Recently, the feasibility of a multitarget assay has been explored (1,2). Because the features of the...

2006
Susan A. Kraegel Paul H. Gumerlock Donald L. Dungworth Victor I. C. Oreffo Bruce R. Madewell

To investigate the role of K-ras mutations in canine non-small cell lung cancer, »etirsi determined the nucleotide sequence of the normal canine K-ras gene and then examined 21 canine lung tumors for acti vating K-ras mutations. Canine K-ras was analyzed by direct sequencing of polymerase chain reaction products generated with oligonucleotide primers derived from the human K-ras sequence. Four...

Journal: :Urology journal 2008
Navaz Karimianpour Parisa Mousavi-Shafaei Abed-Ali Ziaee Mohammad Taghi Akbari Gholamreza Pourmand Amirreza Abedi Ali Ahmadi Hossein Afshin Alavi

INTRODUCTION Studies have shown different types of RAS mutations in human bladder tumors with a wide range of mutation frequencies in different patient populations. This study aimed to assess the frequency of specific-point mutations in the RAS gene family of a group of Iranian patients with bladder cancer. MATERIALS AND METHODS We examined the tumor specimens of 35 consecutive patients with ...

Journal: :The New England journal of medicine 2013
Jean-Yves Douillard Kelly S Oliner Salvatore Siena Josep Tabernero Ronald Burkes Mario Barugel Yves Humblet Gyorgy Bodoky David Cunningham Jacek Jassem Fernando Rivera Ilona Kocákova Paul Ruff Maria Błasińska-Morawiec Martin Šmakal Jean Luc Canon Mark Rother Richard Williams Alan Rong Jeffrey Wiezorek Roger Sidhu Scott D Patterson

BACKGROUND Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouraci...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013
Amélie Trinquand Aline Tanguy-Schmidt Raouf Ben Abdelali Jérôme Lambert Kheira Beldjord Etienne Lengliné Noémie De Gunzburg Dominique Payet-Bornet Ludovic Lhermitte Hossein Mossafa Véronique Lhéritier Jonathan Bond Françoise Huguet Agnès Buzyn Thibaud Leguay Jean-Yves Cahn Xavier Thomas Yves Chalandon André Delannoy Caroline Bonmati Sebastien Maury Bertrand Nadel Elizabeth Macintyre Norbert Ifrah Hervé Dombret Vahid Asnafi

PURPOSE The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome in T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL. Despite this, one third of patients with N/F-mutated T-ALL experienced relapse. PATIENTS AND METHODS In a series of 212 adult T-ALLs included in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید